Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Down 30.9% in March

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 269,500 shares, a decrease of 30.9% from the February 28th total of 389,900 shares. Based on an average daily volume of 333,500 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.6% of the company’s shares are sold short.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in Chemomab Therapeutics during the fourth quarter valued at about $26,000. XTX Topco Ltd lifted its stake in shares of Chemomab Therapeutics by 63.8% in the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after purchasing an additional 9,706 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Chemomab Therapeutics during the 3rd quarter worth about $1,907,000. 46.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Maxim Group lifted their price objective on Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, February 20th.

Chemomab Therapeutics Stock Down 4.9 %

Shares of CMMB stock traded down $0.06 during trading hours on Monday, hitting $1.08. 285,205 shares of the company were exchanged, compared to its average volume of 208,105. The firm has a market cap of $15.44 million, a PE ratio of -1.08 and a beta of 0.54. The firm has a fifty day moving average of $1.70 and a 200 day moving average of $1.68. Chemomab Therapeutics has a 1 year low of $0.58 and a 1 year high of $2.55.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).